anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Periodontitis is one of the low-grade chronic diseases, and it is the principal cause of tooth loss among middle-aged and elderly. Recently, epidemiological data indicate that patients with periodontitis are associated with increases in blood pressure levels and hypertension prevalence. Furthermore, studies from cross-sectional investigations demonstrate that hypertensive patients with periodontitis may enhance the risk and degree of vascular damage. Therefore, periodontal therapy is a novel therapeutic strategy to prevent the occurrence of BP elevation and retard the development vascular injury.

The term "prehypertension" indicates those with BPs ranging from 120 to 139 mm Hg systolic and/or 80 to 89 mm Hg diastolic blood pressure. Accumulating evidence suggests that subjects with prehypertension is associated with higher incidence of atherosclerotic vascular disease. However, until now there are no available data to investigate the influence of periodontitis on prehypertension and whether periodontal intervention may reduce the BP rise in subjects with prehypertension and improve the vascular function. We hypothesized that periodontitis leads to elevation in BP and periodontal therapy improves vascular function in subjects with prehypertension. To address these assumptions, The present study is designed to study the effect of periodontal intervention on blood pressure and vascular function and inflammatory biomarkers among Chinese prehypertensive adults with moderate to severe periodontal disease, and determine whether intensive periodontal therapy improves these measures over a 6-month follow-up period.
Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
ALYREF is considered as a specific mRNA m5C-binding protein which recognizes m5C sites in RNA and facilitates the export of RNA from the nucleus to the cytoplasm. Expressed in various tissues and highly involved in the transcriptional regulation, ALYREF has the potential to become a novel diagnostic marker and therapeutic target for cancer patients. However, few studies focused on its function during carcinogenesis and progress. In order to explore the role of ALYREF on tumorigenesis, TCGA and GTEx databases were used to investigate the relationship of ALYREF to pan-cancer. We found that ALYREF was highly expressed in majority of cancer types and that elevated expression level was positively associated with poor prognosis in many cancers. GO and KEGG analysis showed that ALYREF to be essential in regulating the cell cycle and gene mismatch repair in tumor progression. The correlation analysis of tumor heterogeneity indicated that ALYREF could be specially correlated to the tumor stemness in stomach adenocarcinoma (STAD). Furthermore, we investigate the potential function of ALYREF on gastric carcinogenesis. Prognostic analysis of different molecular subtypes of gastric cancer (GC) unfolded that high ALYREF expression leads to poor prognosis in certain subtypes of GC. Finally, enrichment analysis revealed that ALYREF-related genes possess the function of regulating cell cycle and apoptosis that cause further influences in GC tumor progression. For further verification, we knocked down the expression of ALYREF by siRNA in GC cell line AGS. Knockdown of ALYREF distinctly contributed to inhibition of GC cell proliferation. Moreover, it is observed that knocked-down of ALYREF induced AGS cells arrested in G1 phase and increased cell apoptosis. Our findings highlighted the essential function of ALYREF in tumorigenesis and revealed the specific contribution of ALYREF to gastric carcinogenesis through pan-cancer analysis and biological experiments.
###  Risk Summary

Lorazepam is present in breast milk. There are reports of sedation. poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Lorazepam Injection and any potential adverse effects on the breastfed infant from Lorazepam Injection or from the underlying maternal condition.  
Clinical Considerations   
Infants exposed to Lorazepam injection through breast milk should be monitored for sedation, poor feeding and poor weight gain.  
Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans.  
In a published study in primates, administration of an anesthetic dose of ketamine for 24 hours on Gestation Day 122 increased neuronal apoptosis in the developing brain of the fetus. In other published studies, administration of either isoflurane or propofol for 5 hours on Gestation Day 120 resulted in increased neuronal and oligodendrocyte apoptosis in the developing brain of the offspring. With respect to brain development, this time period corresponds to the third trimester of gestation in the human. The clinical significance of these findings is not clear; however, studies in juvenile animals suggest neuroapoptosis correlates with long-term cognitive deficits (see WARNINGS, Pediatric Neurotoxicity, Pediatric Use, and ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY).
The major goal of our proposed study is to validate a new approach to estimating insulin sensitivity and ß-cell function in African-American women compared to non-Hispanic white women in southern Louisiana who are at a high risk for gestational diabetes mellitus (GDM). We will determine whether the whole body insulin sensitivity index (WBISI) and insulinogenic index (IGI) \[derived from an oral glucose tolerance test (OGTT)\] can be used during 24-28 weeks of pregnancy to accurately estimate the degree of insulin resistance relative to ß-cell function in women with GDM in those with impaired glucose tolerance (IGT) as well as those who are glucose tolerant. Fasting values will also be assessed using the homeostasis model assessment (HOMA-IR and HOMA-%B) to evaluate insulin resistance and ß-cell function. We will explore the potential use of these measures to define the metabolic risk profile of these pregnant women and compare them with obstetric outcomes. We will determine if there are differences in risk that vary by race. Second, given the high likelihood that women who manifest GDM will develop type 2 diabetes mellitus (DM), identification of these patients by ethnic group or other independent determinants will permit intervention after delivery that might delay or prevent the onset of type 2 DM.
<P>PROBLEM TO BE SOLVED: To provide an aqueous wax dispersion fine in particle size, excellent in pH tolerance, salt tolerance and stability, easy to prepare, and flat in emulsified particle stability regardless of ingredients, and a cosmetic with flexibility without spoiling hardness, a wax formulation, and a solid wax composition.  <P>SOLUTION: A polyoxyethylene sorbitol fatty acid ester is obtained by reacting a polyoxyethylene sorbitol prepared by adding an average of 20-100 moles of ethylene oxide to one mole of sorbitol with a 20-40C saturated fatty acid by a mole ratio of 1:2.5-1:5.5 to esterify to an acid value of not greater than 10 mgKOH/g. The cosmetic, and a wax dispersing agent for an aqueous system include the ester. The solid wax composition includes the ester, and a wax. The aqueous wax dispersion includes the ester, the wax, and water, and has a wax content of 0.1-60 mass%, and an ester content of 0.01 pts.mass or more to one pts.mass of the wax. The cosmetics, and the wax formulation includes the dispersion.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
BACKGROUND: Lipid metabolism dysregulation is a key characteristic of hepatocellular carcinoma (HCC) onset and progression. Elevated expression of immunoglobulin (Ig), especially the Igκ free light chain with a unique Vκ4-1/Jκ3 rearrangement in cancer cells, is linked to increased malignancy and has been implicated in colon cancer tumorigenesis. However, the role of Igκ in HCC carcinogenesis remains unclear. The aim of this study was to elucidate the pivotal roles of hepatocyte-derived Igκ in HCC development.
METHODS: The rearrangement sequence and expression level of hepatocyte-derived Igκ in HCC cells were determined via RT-PCR, Sanger sequencing, immunohistochemistry, and western blot analysis. The function of Igκ in HCC tumorigenesis was assessed by silencing Igκ using siRNA or gRNA in various HCC cell lines. To assess the role of Igκ in HCC pathogenesis in vivo, a mouse model with hepatocyte-specific Igκ knockout and diethylnitrosamine (DEN) and carbon tetrachloride (CCL4)-induced HCC was utilized. The molecular mechanism by which Igκ affects HCC tumorigenesis was investigated through multiomics analyses, quantitative real-time PCR, immunoprecipitation, mass spectrometry, immunofluorescence, and metabolite detection.
RESULTS: We confirmed that Igκ, especially Vκ4-1/Jκ3-Igκ, is highly expressed in human HCC cells. Igκ depletion inhibited HCC cell proliferation and migration in vitro, and hepatocyte-specific Igκ deficiency ameliorated HCC progression in mice with DEN and CCL4-induced HCC in vivo. Mechanistically, Vκ4-1/Jκ3-Igκ interacts with electron transfer flavoprotein subunit α (ETFA), delaying its protein degradation. Loss of Igκ led to a decrease in the expression of mitochondrial respiratory chain complexes III and IV, resulting in aberrant fatty acid β-oxidation (FAO) and lipid accumulation, which in turn inhibited HCC cell proliferation and migration.
CONCLUSION: Our findings indicate that the Igκ/ETFA axis deregulates fatty acid β-oxidation, contributing to HCC progression, which suggests that targeting fatty acid metabolism may be an effective HCC treatment strategy. The results of this study suggest that hepatocyte-derived Vκ4-1/Jκ3-Igκ may serve as a promising therapeutic target for HCC.
PURPOSE:An improver for hypoxia, containing a specific benzoxazine derivative or a salt thereof as an active ingredient, having improving action on hypoxia and useful as a cerebral activator, improving drug for consciousness disorder caused by cerebrovascular disorder, etc., drug for senile dementia, etc. CONSTITUTION:An improver for hypoxia containing a benzoxazine derivative expressed by formula I (R<1> is H, lower alkyl or phenyl lower alkyl; R<2> is phenyl which may have 1-3 substituent groups, e.g. halogen or lower alkyl, etc.; A is lower alkylene; Z is O or S) or a salt thereof as an active ingredient. Specifically the improver can be effectively used as a drug for improving consciousness disorder caused by cerebrovascular disorder, encephalitis, cerebral tumor, metabolic disorder, mental diseases, etc., and improving agent for sequelae, deterioration in attentiveness, language disorder, etc., and drug for amnesia, senile dementia, arrhythmia caused by oxygen shortage, drug for cardiac failure, etc. The dose thereof is preferably about 0.2-200mg/kg/day.
The invention discloses a parallel double-channel medical consultation supervision and detection method and model combined with theme information. The model firstly utilizes BERT to generate word vectors, accurately captures word sense details and contexts in the medical professional context, and combines theme vectors generated by CTM to understand text core themes. This fusion strategy enhances both the recognition of offensive language nuances and the understanding of the deep meaning of text. In terms of feature processing, fusion vectors are input to the BiGRU and TextCNN models in parallel to capture complex semantics and local features of text simultaneously. And by splicing the output of the two models, the comprehensive fusion of the characteristics is realized. In addition, the introduced multi-headed attentiveness mechanism further optimizes the feature representation, enabling the model to focus more effectively on key information. The invention has proved to be excellent in offensive language detection in medical professional texts, and has remarkable advantages in distinguishing subtle offensive expressions from conventional medical consultation sentences.
The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). Carbohydrate-rich foods, such as white rice, steamed bread and tubers, were substituted with fish, poultry and plant oil. All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar (106 Kcal: 2.8 g carbohydrate, 11.2 g protein and 5.6 g fat; Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat (i.e., beef, lean pork, skinned chicken, fish) at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
FIELD: technological processes.SUBSTANCE: invention can be used in the manufacture of paper, plastics, paints, adhesives, food, feed, pharmaceutical products, concrete, cement, cosmetics, in water purification and agriculture. For the industrial production of the calcium carbonate-containing material, a substantially non-dispersant aqueous suspension of at least one calcium carbonate-containing material is provided. Aqueous slurry containing a solid in the range of from 10.0 to 80.0 % by weight, based on the total weight of the slurry, is wet-milled to obtain an aqueous suspension of at least one calcium carbonate-containing material with a weight average particle diameter dless than 0.5 mcm. Resulting aqueous suspension is then dewatered, using a mechanical method, to form a filter cake. Resulting filter cake is deagglomerated. Dispersant is then added to the de-agglomerated filter cake and blended to obtain an aqueous slurry containing a solid in the range of 50.0 to 80.0 % by weight, based on the total weight of the aqueous slurry.EFFECT: invention makes it possible to obtain coatings based on a calcium carbonate-containing material having high absorbent and light-scattering properties, improved gloss and the ability to replace titanium dioxide in appropriate applications.17 cl, 2 dwg, 4 tbl, 2 ex
The caregiver gets access to use the app. Each day, investigators will ask the patient to rate their thirst and anxiety and the caregiver to answer daily measures through the application. The caregiver will be asked questions at 3 different times: Day 1, 24-48 hours after enrollment, and 2-4 weeks after the patient is discharged from the ICU. The caregiver will be taught how to use the app. The caregiver will be given the supplies that the caregiver needs to perform the symptom management intervention. Investigators will ask the caregiver to use the app at least once a day, but the caregiver can use it as much as desired while the patient is in the ICU.
Isolated strengthening exercises refers to set of exercises that are used to treat a specific part of body. In our study, isolated strengthening exercises including 10 repetition of 3 sets of legs extensions,10 repetition of 3 sets squats and 10 repetition of 3 sets lunges are used. These exercises aim to improve the pain and range of motion of knee by acting on quadriceps.
A 26-year-old woman presented with a seven-month history of weakness in her left upper limb, progressing to difficulty lifting her arms within a few weeks. Her symptoms progressed with fluctuations. For the past three months, she has been unable to stand due to weakness in her proximal lower limbs. Nerve conduction studies did not show any definite conduction block or abnormal sensory conduction, but motor conduction studies showed a slight prolongation of the terminal latency and a decrease in the frequency of the F-wave. A magnetic fatigue test indicated a proximal conduction block. Her symptoms were rapidly resolved with intravenous immunoglobulin treatment, leading to a diagnosis of chronic immune-mediated neuropathy, met both criteria for multifocal motor neuropathy (MMN) and motor chronic inflammatory demyelinating polyneuropathy (CIDP). Our case highlights the utility of the magnetic fatigue test in detecting conduction blocks and its role in differentiating between MMN and motor CIDP.
A blood sample on a dry tube with a 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 and D3 of the admission to intensive care. The total volume of blood collected for research is therefore 10 ml.
Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
Healthy subjects received 210mg TQC2731 intravenously (iv.) once.
Expression system for components of a desaturase complex is provided. The system includes expression of a desaturase and an oxidoreductase. The system may be used for expression of mycobacterial desaturases or for expression of mammalian desaturases. The system may further include cell-free expression of other components of the desaturase complex. The expression system may include expression of stearoyl-CoA. The expression system may further include expression of cytochrome b5. The expression system may also include expression of cytochrome b5 reductase. The expression system may also include expression of Rv3230c. In addition, methods for assaying the activity of a stearoyl-CoA desaturase in vitro are provided.
Infliximab is approved for induction and maintenance of clinical remission and mucosal healing in patients with moderate to severe active ulcerative colitis, in those who have an inadequate response to conventional therapy such as IV steroids. It is typically dosed at 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. The alternative to rescue medical therapy with infliximab is proctocolectomy with ileal pouch anastomosis, which carries risks including pouchitis, fecal incontinence, pouch failure requiring further surgical procedures and female infertility, or proctocolectomy with permanent end-ileostomy, which many patients wish to avoid. The induction regimen of 3 doses of Infliximab followed by a maintenance dose every 8 weeks is used to achieve response in hopes of avoiding colectomy. Unfortunately, a large proportion of patients are unable to achieve or sustain a clinical response over time and end up getting a colectomy.

Potential implicated pathways in non-responders include fecal wasting of infliximab and factors that accelerate drug clearance such as a large TNF (tumor necrosis factor) or CRP (C reactive protein) burden, anti-infliximab antibodies (ATI), low serum albumin, male sex and larger body size. Patients with severe ulcerative colitis who fail corticosteroids and standard dosing with infliximab usually proceed to proctocolectomy. Optimizing early infliximab blood levels in patients with moderate-severe ulcerative colitis by administering the second dose of infliximab before week 2 could improve the efficacy and further reduce the need for colectomy. However, there is a paucity in the literature as this is a relatively new school of thought. Our study will address this deficit by evaluating the relationship between early drug levels of infliximab in ulcerative colitis and colectomy rates at one and three months.
The present invention relates to a user registration system and method of a wearable device for a hospital by using a quick response (QR) code, which can enable a user to conveniently register and manage use information related to a wearable device supplied to a patient by using a QR code. The system of the present invention comprises: a wearable device; a server connected to a network; a platform installed on the server; a QR code generator; and a QR code reader for recognizing a QR code from a QR code sticker outputted by the QR code generator. According to the method of the present invention, a device ID number for a wearable device which can be worn by a patient can be registered through a platform on a server connected to a network, and a QR code sticker having a QR code including the device ID number and a URL address which enables a user to access the platform can be outputted. After the QR code sticker is attached to the wearable device, the device use information on the wearable device can be registered through the platform accessed by recognition of the QR code. The device use information consists of a device ID number, a hospital ID number, a registration date, a hospital room number, and a bed number except for information on a patient. According to the present invention, the QR code sticker is attached to a wearable device supplied to a patient and the device use information is registered in the platform through QR code recognition and password authentication, thereby systemically and efficiently allowing treatment and management of the patient through the wearable device and the QR code while safely protecting individual information on the patient.
1437835 Sustained iodine release COMMONWEALTH SCIENTIFIC & INDUSTRIAL RESEARCH ORGANIZATION 5 June 1974 [14 June 1973 24878/74 Heading A5B A device for providing controlled and sustained release of iodine to animals, particularly ruminants, comprises a sealed envelope of plasticised or unplasticised polyvinylchloride, a nylon, a polyethylene or a polypropylene, permeable to iodine, and which contains elemental iodine or a source of iodine. The administration may be oral or by surgical implantation. The device of Fig. 4C consists of a rubber disc 1 which has a central aperture 2, in which is a polyethylene capsule 3 containing the iodine or source of iodine. Capsule 3 is shown in detail in Figs. 4B and 4A. Body 4 has a socket 6 which extends into a cavity 7, and a slot 8, into which plug 5 is fitted. The iodine or source of iodine is placed in 7 and the capsule is held in place in the disc 1 by engaging the slots 8 and 10 therein. The devices may be in the form of, or incorporated into, tihe devices of U.K. Specification 1318259.